MeiraGTx Reports Second Quarter 2023 Financial and Operational Results

Phase 3 LUMEOS clinical trial of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) enrollment target has now been surpassedAnnounced positive clinical data from the completed AQUAx Phase 1 study of AAV2-hAQP1 for the treatment of grade 2/3 radiation-induced xerostomia (RIX), showing bilaterally treated participants reaching normal levels of whole saliva flow rate by 2 months post-treatment and persisting through the final Month 12

Related Keywords

Ireland ,London ,City Of ,United Kingdom ,United States ,American ,Jason Braco ,Association For Research ,Lifesci Communications ,American Society Of Gene ,Meiragtx Holdings ,Nasdaq ,Cell Therapy ,Alexandria Forbes ,Development Highlights ,Anticipated Milestones ,Induced Xerostomia ,Owned Gene Therapy Manufacturing Facility ,Received Commercial ,Gene Regulation Platform ,Vector Engineering ,Private Securities Litigation Reform Act ,Quarterly Report ,Six Month Period Ended June ,Meiragtx ,Gene Regulation ,Gene Therapy ,Clinical Programs ,Clinical Stage ,Shannon ,Clinical Trials ,